Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)–tricarbonyl complexes

This study aims at the synthesis and initial biological evaluation of novel rhenium–tricarbonyl complexes of 3,3′,4′,5,7-pentahydroxyflavone (quercetin), 3,7,4΄-trihydroxyflavone (resokaempferol), 5,7-dihydroxyflavone (chrysin) and 4΄,5,7-trihydroxyflavonone (naringenin) as neuroprotective and anti-PrP agents. Resokaempferol was synthesized from 2,2΄,4-trihydroxychalcone by H2O2/NaOH. The rhenium–tricarbonyl complexes of the type fac-[Re(CO)3(Fl)(sol)] were synthesized by reacting the precursor fac-[Re(CO)3(sol)3]+ with an equimolar amount of the flavonoids (Fl) quercetin, resokaempferol, chrysin and naringenin and the solvent (sol) was methanol or water. The respective Re–flavonoid complexes were purified by semi-preparative HPLC and characterized by spectroscopic methods. Furthermore, the structure of Re–chrysin was elucidated by X-ray crystallography. Initial screening of the neuroprotective properties of these compounds included the in vitro assessment of the antioxidant properties by the DPPH assay as well as the anti-lipid peroxidation of linoleic acid in the presence of AAPH and their ability to inhibit soybean lipoxygenase. From the above studies, it was concluded that the complexes’ properties are mainly correlated with the structural characteristics and the presence of the flavonoids. The flavonoids and their respective Re-complexes were also tested in vitro for their ability to inhibit the formation and aggregation of the amyloid-like abnormal prion protein, PrPSc, by employing the real-time quaking-induced conversion assay with recombinant PrP seeded with cerebrospinal fluid from patients with Creutzfeldt–Jakob disease. All the compounds blocked de novo abnormal PrP formation and aggregation. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s00775-022-01986-9.


Introduction
Neurodegenerative disease is currently the seventh leading cause of mortality especially among older people worldwide, and Alzheimer's disease (AD) contributes to approximately 60-70% of the cases. Neurodegenerative diseases are typically defined by specific protein accumulations and are classified, as amyloidoses, tauopathies, a-synucleinopathies, and transactivation response DNA binding protein 43 (TDP- 43) proteinopathies. In addition, neurodegenerative diseases share other pathological features, such as progressive neuronal dysfunction and death, which are associated among others with oxidative stress and neuroinflammation [1,2].
Amyloidoses are characterized by insoluble amyloid fibrous proteins that have specific structural characteristics, including a rich β-sheet secondary structure, which permits binding of fluorescent dyes, such as Thioflavin T and Congo red. In AD β-amyloid (Aβ) peptide deposits are formed as a proteolytic product of the amyloid precursor protein. In prion disease the pathogenic isoform of the prion protein (PrP Sc ) is deposited in an amyloid-like formation, after conversion of the normal protein isoform (PrP C ) to it abnormal counterpart. Studies have shown that once formed, the PrP Sc behaves as a "seed" and the aberrant proteins propagate by acting as templates to corrupt other like molecules, produced physiologically in the cell. The prion concept has expanded to include many of the aberrant proteins that characterize neurodegenerative diseases [3,4]. A proposed mechanism, in amyloidogenic disease, entails a process where the native protein forms folded or unfolded oligomers that accelerate aggregation to fibrils. In this light, therapeutic strategies targeted to the aggregation process have attracted a lot of interest and several agents have shown promising results in clinical trials [5].
Oxidative stress is the accumulation of reactive oxygen species (ROS) in the cells, causing cellular dysfunction and lipid peroxidation is the oxidative damage of lipids as a result of the action of ROS and both are conditions that contribute to the pathological features of neurodegenerative disorders [6]. A number of neuroprotective agents have shown to inhibit lipid peroxidation, and among these flavonoids have shown promising results [7][8][9][10][11][12]. Flavonoids are natural polyphenolic compounds ubiquitous in vegetables, fruits, tea and other plants that exhibit a wide variety of biological activities, rendering thus the flavone scaffold attractive in drug design [13]. In addition, polyphenols and natural flavonoids, as well as their synthetic derivatives, demonstrate inhibition of cholinesterase, of β-secretase as well as inhibition of toxic β-amyloid formation and, therefore, have attracted increasing attention in the development of multi-targeted therapeutic agents against neurodegeneration [14][15][16][17][18][19][20][21][22][23][24][25]. In addition, flavonoid-metal complexes were shown to exhibit anti-oxidative properties [26,27]. Derivatized flavonoids and chemically related structures (aurones) were radiolabeled with fluorine-18, a radionuclide used in positron emission tomography as well as with technetium-99 m, a γ-emitting radionuclide used in single photon emission computerized tomography [28][29][30] and were evaluated as radiodiagnostic agents due to their affinity to bind to β-amyloid plaques.
Metal complexes play an important role in medicinal chemistry, especially in theranostic approaches [31,32]. Facial rhenium (I)-tricarbonyl complexes are attracting interest as building blocks for pharmaceutical applications, due to their demonstrated kinetic stability, structural and substitution flexibility, and anticancer properties. [33][34][35] Re(I)-tricarbonyl complexes with polyaromatic ligands exhibit fluorescent properties with potential as fluorescent probes for fluorescence microscopy imaging [36][37][38]. Furthermore, rhenium can also be used for the development of multi-targeted complexes by coordination of different pharmacophores around the metal core that is extremely useful in neurodegenerative multifactorial diseases with complex biochemistry. [39,40] In addition, due to the chemical similarity between rhenium and technetium, the rhenium(I)-tricarbonyl complexes can be used as prototypes for the development of analogous [ 99m Tc][Tc(I)-tricarbonyl complexes as SPECT radiodiagnostic agents.
In this work, the flavonoids 3,3′,4′,5,7-pentahydroxyflavone (quercetin), 3,7,4΄-trihydroxyflavone (resokaempferol), 5,7-dihydroxyflavone (chrysin) and 4΄,5,7-trihydroxyflavonone (naringenin) were complexed with rhenium-tricarbonyl (Fig. 1). The elucidation of the coordination site of quercetin with rhenium-tricarbonyl was supported by the characterization of Re-resokaempferol, Re-chrysin and Re-naringenin chelates. The complexes were evaluated for their anti-oxidant properties, for their ability to inhibit lipid peroxidation and to inhibit lipoxyhenase in comparison to the free flavonoids, since the role of oxidative stress and lipoxygenase's pathway in neurodegenerative diseases is well known [41] Furthermore, the flavonoids and their rhenium complexes were evaluated for their ability to inhibit PrP Sc formation and aggregation from human prion disease samples in cellfree assays.
IR spectra were recorded as KBr pellets on a Spectrum BX spectrophotometer (Perkin Elmer, Waltham, MA, USA) in the region 4000-500 cm −1 . Elemental analysis was performed with ThermoFlash 2000 analyzer (Thermo Scientific, Waltham, MA, USA). 1 H and 13 C NMR spectra were obtained on a DD2 Agilent 500 MHz spectrometer. ESI-MS data were obtained on an MSQ Plus™ LC/ MS (Thermo Scientific, Waltham, MA, USA). Hitachi F2000 Fluorospectrometer was used for emission spectra. HPLC analyses were performed on an Agilent HP 1100 series pump (HP, Waldbronn, Germany), connected to an HP 1100 multiple wavelength photodiode array detector. RP-HPLC analyses of the rhenium complexes were performed on an Agilent Eclipse XDB C18 column (25 cm × 4.6 mm, 5 μm) by applying a binary gradient method of Solvent A: H 2 O and Solvent B: methanol at a flow rate of 1 mL/min; System I: 100% of A initial composition that linearly converted to 25% A-75% B over 15 min, then to 5% A-95% B over 5 min. The composition was constant from 20 to 25 min at 95% B, before returning to initial conditions. Purification of the rhenium complexes was performed by semi-preparative HPLC on an Eclipse XDB C18 column (25 cm × 9.4 mm, 5 μm) by applying a binary gradient method of Solvent A: H 2 O and Solvent B: methanol at a flow rate of 2 mL/min; System II: 50% of A initial composition that linearly converted to 25% A-75% B over 15 min, then to 5% A-95% B over 5 min. The composition was constant from 20 to 25 min at 95% B, before returning to initial conditions. System III: 60% of A initial composition that linearly converted to 25% A-75% B over 15 min, then to 5% A-95% B over 5 min. The composition was constant from 20 to 25 min at 95% B, before returning to initial conditions. The antioxidant properties of the compounds were measured on a PerkinElmer lambda 20 (PerkinElmer Inc., Waltham, MA, USA) or on a Shimadzu, UV-1700 Spectrophotometer (Shimadzu Corp, Kyoto, Japan).

Synthesis of 3,7, 4′-trihydroxyflavone (resokaempferol)
Adapted from the literature [44,45], to a methanolic solution of 2,2',4-trihydroxychalcone (0.5 mmol), NaOH 2 M (3 mL) was added. A 30% aqueous solution of H 2 O 2 (225 μL) was then added dropwise and the reaction mixture was stirred at room temperature for 24 h. The mixture was acidified by addition of HCl 5 N and the yellow solid received was filtered and recrystallized from methanol.

X-ray crystallography of Re-chrysin
Crystals of fac-[Re(CO) 3 (chrysin)(MeOH)]0.2MeOH were taken from the mother liquor and mounted at − 143 °C on a Bruker Kappa APEX2 (Bruker Corp., Billerica, Ma, USA) diffractometer equipped with a triumph monochromator using Mo Kα radiation. Unit cell dimensions were determined and refined by using the angular settings of 487 high intensity reflections (> 10 σ(I)) in the range 15 < 2θ < 40°. Intensity data were recorded using φ and ω scans. Crystal presented no decay during the data collection. The frames collected were integrated with the Bruker SAINT software package [46], using a narrow-frame algorithm. Data were corrected for absorption according to the literature [47]. The structure was solved using the Shelxs86 package [48]. Data refinement (full-matrix least-squares methods on F 2 ) and all subsequent calculations were carried out using Crystals program package version 14.61 build 62.36 [49,50]. Molecular illustrations with 50% ellipsoid probability were drawn using CAMERON incorporated into crystals [51,52].
All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were located by difference maps at their expected positions and refined using soft constraints. By the end of the refinement, they were positioned geometrically using riding constraints to bonded atoms. Crystal data as well as details of data collection and structure refinement for the compounds are given in Table 1. Further details on the crystallographic studies as well as atomic displacement parameters are given as Supporting Information in the form of cif files.
CCDC 2126509 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www. ccdc. cam. ac. uk/ data_ reque st/ cif, or by emailing to data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: + 44 1223336033.

In vitro assays
The in vitro assays were performed at a concentration of 100 µM (a stock solution 10 mM in DMSO was used, from which several dilutions were made for the determination of IC 50 values), at least in triplicate and the standard deviation of absorbance was less than 10% of the mean. The compounds were diluted as 0.1% DMSO under sonication in the appropriate buffer in several dilutions (Table 2).
i. Determination of the reducing activity of the stable radical DPPH [53] To an ethanolic solution of DPPH (50 μΜ) in absolute ethanol, an equal volume of the compounds dissolved in DMSO was added (100 μΜ). The mixture was shaken vigorously and allowed to stand for 20 min or 60 min; absorbance at 517 nm was determined spectrophotometrically and the percentage of activity was calculated. All tests were performed in triplicates and the results were averaged (Table 2). NDGA was used as a standard reference compound.
ii. Inhibition of linoleic acid lipid peroxidation [53] Production of conjugated diene hydroperoxide by oxidation of linoleic acid in an aqueous dispersion is monitored at 234 nm. AAPH is used as a free radical initiator. This assay can be used to follow oxidative changes and to understand the contribution of each tested compound. The experimental procedure follows our previously reported protocol.
In 16 mM linoleic acid sodium salt solution, 10 µL of the tested compounds (final concentration 100 μΜ) was added to the UV cuvette containing 0.05 M phosphate buffer, pH 7.4 preheated to 37 °C. The oxidation reaction was initiated at 37 °C under air by the addition of 40 mM AAPH solution. Oxidation was carried out in the presence of the tested compounds in the assay without antioxidant, lipid oxidation was measured in the presence of the same level of DMSO. The rate of oxidation at 37 °C was monitored by recording the increase in absorption at 234 nm caused by conjugated diene hydroperoxides. Trolox was used as a standard reference compound.

3
The tested compounds dissolved in DMSO (a stock solution 10 mM in DMSO was used) were incubated at RT with sodium linoleate and 0.2 ml of enzyme solution (1/9 × 10 -4 w/v in saline) in Tris buffer, pH 9, and 10 µL of the tested compounds (final concentration 100 μΜ) were added. The conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 234 nm was recorded and compared with the appropriate standard inhibitor NDGA. The IC 50 values were calculated for Re-naringenin and Re-quercetin by performing the measurements at several dilutions.

RT-QuIC assays
Real-time quaking-induced conversion (RT-QuIC) reactions are cell-free assays, currently used to estimate whether compounds can impede the conversion of the normal isoform of the prion protein (PrP C ) into PrP Sc , the abnormally folded, disease-associated, prone to aggregate isoform [54]. Assays were performed as previously described [55]. In brief, 15 μl of cerebrospinal fluid (CSF) from patients with sporadic Creutzfeldt-Jakob disease (sCJD) diluted 10 3 -fold in 1 × phosphate buffered saline (PBS) were mixed with 85 μl of reaction buffer consisting of 5 × PBS (pH 6.9), 170 mM sodium chloride, 1 mM EDTA, 10 μM Thioflavin-T and 0.1 mg/mL recombinant PrP (hamster-sheep chimera sequence). The lead and the labelled compounds were diluted in DMSO and added to a final concentration of 1 and 20 μΜ at the beginning of the reactions, to evaluate whether they would efficiently inhibit the conversion of PrP C to PrP Sc and the aggregation of the later. To rule out any non-specific effects Control reactions, in which CSF from healthy individuals instead of CJD patients was added along with the compounds, and DMSO only reactions, wherein no compound was added were also included. The reactions were setup in 96-well black optical bottom plates and carried out in a FLUO Star OPTIMA (BMG Labtech, Ortenberg. Baden-Württemberg, Germany plate reader at 42 °C for 80 h with intermittent quaking cycles (double-orbital quaking at 600 rpm: one minute, incubation break: one minute). Kinetics of the beta-sheet formation were monitored by Thioflavin T fluorescence (excitation 450 nm, emission 480 nm) every 30 min. To rule out any non-specific effects Control reactions, in which CSF from healthy individuals instead of CJD patients was added, and DMSO only reactions, wherein no compound was added were also included.

Synthesis and characterization
The preparation of resokaempferol was performed by alkaline cyclization in NaOH solution and subsequent addition of hydrogen peroxide (Scheme 1).
The preparation of the rhenium complexes was performed by reaction of the precursor fac-[Re(CO) 3  In the 1 H-NMR spectra of the rhenium complexes of 3-resokaempferol and quercetin, a significant downfield shift of the B flavone ring protons 2' and 6' was observed due to the metal coordination at the C-4 carbonyl oxygen and the C-3 phenolic oxygen of the C flavone ring (Fig. 2). In particular, H-2'/H-6' protons shifted from 8.11 to 8.41 ppm in Re-resokaempferol and from 7.71/7.57 to 8.07/7.92 ppm in Re-quercetin, respectively. Furthermore, in the 13 C-NMR there was a downfield shift of C-3 from 137 to 150 ppm and of C-4 from 173 to 182 ppm in Re-resokaempferol. Respectively, in Re-quercetin, a shift of C-3 from 137 to 151 ppm and a shift of C-4 from 176 to 182 ppm was observed. The shifts of the Re-coordinated carbonyl ligands are at 198 ppm in both Re-resokaempferol and Re-quercetin. On the other hand, in the rhenium complexes of naringenin and chrysin the shifts of ring B protons remain undisturbed. In the 1 H-NMR of the Re-chrysin complex (Fig. 2), H-8 proton shifted from 6.52 to 6.32 ppm and in the 13 C-NMR spectrum C-4 shifted from 182 to 178 ppm, C-5 from 162 to 166 ppm and C-10 from 105 to 108 ppm. The shifts of the Re-coordinated The emission spectra of the complexes in concentration 10 μΜ were recorded using their absorbance maximum for excitation λ. Data are shown in Fig. S1 for Re-resokaempferol and Re-quercetin that exhibited the highest emission.
Re-resokaempferol exhibited maxima at 416 and 438 nm after excitation at 346 nm. Re-quercetin exhibited maximum at 525 nm after excitation at 470 nm.

X-ray crystallography of rhenium-chrysin complex
A diagram of the structure of complex Re-chrysin is depicted in Fig. 3, bond distances and angles (Table S1) and hydrogen bonding data (Table S2) [56,57] and oxolinic acid [58], as well as five-membered ring forming bidentate chelators, such as tropolonato [59] and 3-hydroxyflavone [60]. Two solvent molecules of methanol are also present in the structure of the asymmetric unit. Hydrogen bonding interactions between the carbonyl and phenolic oxygen atoms of the ligand, and the oxygen atoms of the alcoholic group of the solvate and ligated methanols are also present.

In vitro assays
A prominent property of flavonoids is that, through their antioxidant ability, they might provide protection against oxidative stress. The antioxidant activity of flavonoids and other polyphenols is attributed primarily to their ability to scavenge reactive oxygen and nitrogen species [61]. In this study, the rhenium complexes of three flavones and one flavanol were tested as antioxidant agents and inhibitors of lipoxygenase. Antioxidants acting as lipid peroxidation inhibitors could offer health maintenance and compensation of risk factors [62].
The evaluation of the Re-complexes against soybean lipoxygenase LOX was accomplished by the UV-based enzyme assay of Hadjipavlou-Litina et al. [63]. This assay may be used for qualitative or semi-quantitative screen for such activity [64]. Chrysin and Re-chrysin exhibited very low LOX inhibition, which may be explained by the absence of a phenolic moiety in the B-ring of chrysin (Table 2). Significant decrease in LOX inhibition was observed for the other rhenium complexes compared to the respective flavonoids (Table 2). We decided to determine the IC 50 values for quercetin and Re complex since both present high interaction activity with DPPH after 60 min and high inhibition of lipid peroxidation. Quercetin exhibits high inhibition of LOX with IC 50 value of 4.75 μM and Re-quercetin IC 50 of 35 μΜ, under the experimental conditions, respectively. The order of LOX inhibition for the Re-complexes was Re-quercetin > Re-resokaempferol > Re-naringenin. The biological results of Re-quercetin are mainly correlated with the structural characteristics and the presence of quercetin [9,65].
The antioxidant activity of a compound must be evaluated in a variety of milieus, since factors like solubility or steric hindrance must be considered. Thus, several different assays must be used to avoid conflicts. Also, in each protocol the generation of a different radical is taking place. Two types of experimental approaches have been considered: (i) the assays in which we have the scavenging by hydrogen-or electron donation of a preformed free radical as a marker of antioxidant activity as well as (ii) assays involving the presence of an antioxidant system during the generation of the radical.
The Re-complexes were studied for their antioxidant activity by the use of the 2,2-diphenyl-1-picrylhydrazyl radical (DPPH) at concentration 100 µM after incubation for 20 and 60 min (Table 2). In the DPPH assay, the dominant chemical reaction involved is the reduction of the DPPH radical by single electron transfer (SET) from the antioxidant. Phenolic compounds, e.g. NDGA giving phenoxide anions are effective antioxidants. All the Re-complexes (with the exception of Re-chrysin) interact with the free stable radical DPPH. Re-quercetin presents lower antioxidant activity than quercetin at 20 min. On the contrary, the reducing abilities of Re-naringenin and Re-resokaempferol are higher compared to the flavonoids. The antioxidant activities of resokaempferol, naringenin as well as of Re-resokaempferol and Re-naringenin complexes do not seem to be influenced over the time. The measured antioxidant properties for chrysin and its complex are insignificant, likely due to the absence of a hydroxyl moiety in the B-ring. In the literature, Zn complexes of chrysin and quercetin exhibited enhanced radical scavenging potential [26].
The Re-flavonoid complexes were assessed in vitro for their ability to inhibit peroxidation of linoleic acid in the presence of AAPH, an azo compound generating free radicals through spontaneous thermal decomposition. AAPH has been used in in vitro model of oxidative stress. The activity of the peroxyl radicals produced by the action of AAPH greatly resembles cellular activities such as lipid peroxidation and used to mimic the oxidative stress state.
Re-quercetin is the only complex with anti-lipid peroxidation activity, which is equipotent to that of quercetin. Quercetin affects immunity and inflammation by acting mainly on leukocytes and targeting many intracellular signaling kinases and phosphatases, enzymes and membrane proteins often crucial for a cellular specific function and it was found to inhibit in particular rabbit reticulocyte 15-lipoxygenase-1 (EC 1.13.11.33) [66] and recombinant human 5-lipoxygenase (EC 1.13.11.34) [67].
Most of the LOX inhibitors present antioxidant activity or act as free radical scavengers [68], since lipoxygenation occurs via a carbon centered radical. Herein the anti-lipid peroxidation results for the Re-quercetin complex support the anti-lipoxygenase activity. Analogous results of free quercetin and other flavonoids have been reported in the literature [9,65].
Free radicals are highly implicated in lipoxygenase inhibition, inflammation, cancer and neurodegeneration. Thus, compounds possessing these activities in combination with antioxidant activity might offer to the prophylaxis or therapy of these diseases.

RT-QuIC assays
RT-QuIC assays provide a fast and efficient way to screen compounds for their anti-aggregation properties in a cellfree setting and the use of RT-QuIC and similar approaches has expanded considerably throughout the past few years both for diagnosis and for drug development [69]. The free flavones and their rhenium complexes were used in RT-QuIC assays to evaluate their anti-aggregation properties in sCJD. sCJD is the most common form of Transmissible Spongiform Encephalopathy and is associated with the conversion of the cellular form of the prion protein (PrP C ) to its disease associated and aggregation-prone counterpart (PrP Sc ).
In our setting, PrP Sc from the CSF of patients with confirmed sCJD was used as the seed for the conversion of recombinant PrP (rPrP), which is soluble and cannot form aggregates. Throughout repeating RT-QuIC cycles, the tertiary structure of rPrP molecules is altered and novel aggregation-prone, PrP Sc -like molecules are formed. This structural conversion is monitored via the incorporation of Thioflavin T and the recording of the fluorescence emission [70].
The compounds were initially diluted in DMSO and were added to the reaction mix in a final concentration of 20 μM or 1 μΜ (with the exception of Chrysin that was only tested at a final concentration of 20 μM). Each assay was repeated in triplicates and the fluorescence data (relative fluorescence data, RFU) were recorded every 30 min for 80 h (Fig. 4). As expected, in control assays in which only DMSO was added, PrP C was successfully converted to PrP Sc , yielding the highest RFU readouts. On the other hand, all the compounds successfully inhibited the conversion of PrP C to the diseaseassociated isoform PrP Sc when added at a final concentration of 20 μM. In this case, the RFU readouts upon addition of the compounds remained low throughout the assay and matched those of the Control reactions wherein the pathogenic seed had not been added. This effect appears to be dose related: even though rigorous dose-response experiments were not performed, when lower concentrations of the compounds were added to the reaction mix, PrP C conversion was only moderately inhibited. Dose-response experiments would also provide more detailed information on the effect chemical modification has on the anti-aggregation properties of the compounds. Our initial data indicate that the conversion of the free flavonoids to their rhenium complexes did not result in loss of their ability to inhibit the formation of PrP Sc , indicating that these complexes retain their activity. Preliminary data also indicates that the compounds can solubilize already formed aggregates. In modified RT-QuIC assays, we added the compounds after the PrPSc aggregates had been formed, as evidenced by the fluorescence readouts. In this setting, we observed that the compounds produced a gradual decrease of the fluorescence, indicating a reduction of the PrP Sc aggregates (Fig. S2). These data imply that the compounds may not only have a protective role, but also a therapeutic.
Even though the conversion mechanism has not yet been defined, it has been suggested that similar conversion and aggregation mechanisms could be involved in other neurodegenerative proteinopathies as well, including Alzheimer's and Parkinson's [71] diseases thus indicating that the compounds developed could be useful as theranostics in the whole spectrum of neurodegenerative diseases (Fig. 4).

Conclusions
The synthesis of the rhenium-tricarbonyl complexes of a variety of flavonoids that belong to the class of either 3-flavonols, such as resokaempferol and quercetin, of flavones, such as chrysin and of flavanones, such as naringenin was reported. Based on spectroscopic data the complexation takes place via the carbonyl and the neighboring hydroxyl group, either (O4-O3) or (O4-O5) and the complexes exhibit comparable stability in solution. In Re-quercetin, NMR data indicate that the coordination via the carbonyl O4 and 3-hydroxyl O occurs. All complexes exhibited anti-oxidant properties against the DPPH radical, with the exception of Re-chrysin. LOX inhibition was observed for the Recomplexes of resokaempferol, quercetin, naringenin, which was lower compared to the free flavonoid. Re-quercetin exhibited the highest LOX inhibition and antioxidant and anti-lipid peroxidation properties among the complexes. Furthermore, all the tested compounds blocked de novo abnormal PrP formation and aggregation in cell free systems. Prompted by these promising results, future studies to determine the ability of Re-quercetin and Re-resokaempferol as fluorescent probes to detect amyloid plaques are envisioned. In addition, these complexes could be used for the design of multi-targeted Re-tricarbonyl "2 + 1" complexes for therapy as well as "2 + 1" technetium-99 m-tricarbonyl complexes for amyloid-targeted scintigraphy.
Funding Open access funding provided by HEAL-Link Greece.

Conflict of interest
The authors have no relevant financial or non-financial interests to disclose. No funding was received for conducting this study.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.  (20 μΜ) was also added to control reactions, in which CSF from healthy individuals that did not contain the pathogenic PrP Sc isoform was used as the seed. Furthermore, DMSO only control reactions (DMSO), in which DMSO with a final concentration corresponding to the one obtained with the higher compound concentration and CSF from sCJD patients were used as positive control reactions